Domenico Capone1, Mauro Cataldi1,2, Mauro Vinciguerra3, Teresa Mosca1, Salvatore Barretta4, Annalisa Ragosta4, Aniello Sorrentino5, Alessandra Vecchione5, Luca Barretta5, Giovanni Tarantino6. 1. Integrated Care Department of Clinical Neurosciences, Anestesiology and Drug-Use, Section of Clinical Pharmacology, "Federico II" University, Naples, Italy. 2. Division of Pharmacology, Department of Neuroscience, Reproductive and Odontostomatologic Sciences, "Federico II" University of Naples, Naples, Italy. 3. Section of Nephrology, Santa Maria Delle Grazie Hospital, Pozzuoli, Italy. 4. Outpatients Clinic of Hemodialysis Dial Center s.r.l. Pomigliano D'Arco, Naples, Italy. 5. Diagnostic Center Kappa SRL Pomigliano D'Arco, Naples, Italy. 6. Department of Clinical Medicine and Surgery, "Federico II" University, Naples, Italy tarantin@unina.it.
Abstract
BACKGROUND/AIM: Anemia in patients suffering from end-stage renal failure is currently treated with Erythropoiesis-Stimulating Agents (ESA). This treatment needs sufficient iron supplementation to avoid an inadequate dosage of ESA. Nowadays modern analytical instruments allow to accurately calculate the content of Hemoglobin (Hb) in reticulocytes (CHr), that can be used as a guide for prescribing patients with the appropriate amount of iron. PATIENTS AND METHODS: Patients, undergoing hemodialysis, were retrospectively selected from the database and were divided in two groups: group A received intravenous (IV) iron and subcutaneously ESA, and their dosages were adjusted on the basis of the following parameters: Hb, Mean corpuscular haemoglobin (MCH), CHr with consequent MCH/CHr ratio and reticulocyte count determined by the ADVIA 120 Hematology System of Siemens; group B patients were administered IV iron and ESA monitoring iron storage, Hb and ferritin. The aforementioned parameters and the administered amount of iron and ESA were monitored at baseline, four and eight months from the begining of the study. RESULTS: For ESA supplementation, no difference was observed between the groups at the various observed times. Despite similar Hb levels, the patients of group A needed significant lower doses of IV iron (-57.8%) avoiding risks of organ toxicity and obtaining consequent cost saving of nearly 1 €/patient/month. CONCLUSION: The use of CHr and its related parameters allows the avoidance of overdosage of IV iron, which can potentially damage organs, and the reduction of health care direct and indirect costs. Copyright
BACKGROUND/AIM: Anemia in patients suffering from end-stage renal failure is currently treated with Erythropoiesis-Stimulating Agents (ESA). This treatment needs sufficient iron supplementation to avoid an inadequate dosage of ESA. Nowadays modern analytical instruments allow to accurately calculate the content of Hemoglobin (Hb) in reticulocytes (CHr), that can be used as a guide for prescribing patients with the appropriate amount of iron. PATIENTS AND METHODS: Patients, undergoing hemodialysis, were retrospectively selected from the database and were divided in two groups: group A received intravenous (IV) iron and subcutaneously ESA, and their dosages were adjusted on the basis of the following parameters: Hb, Mean corpuscular haemoglobin (MCH), CHr with consequent MCH/CHr ratio and reticulocyte count determined by the ADVIA 120 Hematology System of Siemens; group B patients were administered IV iron and ESA monitoring iron storage, Hb and ferritin. The aforementioned parameters and the administered amount of iron and ESA were monitored at baseline, four and eight months from the begining of the study. RESULTS: For ESA supplementation, no difference was observed between the groups at the various observed times. Despite similar Hb levels, the patients of group A needed significant lower doses of IV iron (-57.8%) avoiding risks of organ toxicity and obtaining consequent cost saving of nearly 1 €/patient/month. CONCLUSION: The use of CHr and its related parameters allows the avoidance of overdosage of IV iron, which can potentially damage organs, and the reduction of health care direct and indirect costs. Copyright
Authors: J S Kaufman; D J Reda; C L Fye; D S Goldfarb; W G Henderson; J G Kleinman; C A Vaamonde Journal: N Engl J Med Date: 1998-08-27 Impact factor: 91.245
Authors: Francesco Locatelli; Adrian Covic; Kai-Uwe Eckardt; Andrzej Wiecek; Raymond Vanholder Journal: Nephrol Dial Transplant Date: 2008-11-26 Impact factor: 5.992